Soluble guanylate cyclase (sGC) stimulation or sodium-glucose cotransporter 2 (SGLT2) inhibition may improve cardiovascular, renal, and metabolic function in settings of hypertension and obesity. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.